Active, not recruitingPhase 3NCT06548100
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Studying Acquired generalized lipodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- mibavademab(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2024 – 2026
Study locations (2)
- National Institutes of Health, Bethesda, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06548100 on ClinicalTrials.govOther trials for Acquired generalized lipodystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07220785Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyRegeneron Pharmaceuticals
- RECRUITINGPHASE3NCT06502990Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised LipodystrophyAmryt Pharma
- ACTIVE NOT RECRUITINGNANCT03936829Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 DiabetesChildren's Hospital of Fudan University
- RECRUITINGNCT03553420Registry for Patients With LipodystrophyUniversity of Ulm
- ACTIVE NOT RECRUITINGPHASE3NCT02262832Compassionate Use of Metreleptin in Previously Treated People With Generalized LipodystrophyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)